Insights from Brain’s Waste-Flushing System May Improve Diagnosis of Idiopathic Intracranial Hypertension
MRI analysis that measures the activity of the glymphatic system may offer a noninvasive method for diagnosing unexplained brain pressure.
Weather AlertWe are monitoring the weather's impact on our services. If you are experiencing a medical emergency, call 911 or go to the nearest emergency department. Mass General Brigham's emergency departments remain open. For real-time updates and service changes, please check our Alerts page.View Alerts page
Press Release5 Minute ReadFeb | 2 | 2021
Elizabeth Atkinson, PhD,We can get more powerful and precise genetic association signals and do a better job at pinpointing where the causal mutation is, which improves our understanding of disease for everyone.
BOSTON -- Genome-wide association studies (GWAS) have typically excluded diverse and minority individuals in the search for gene variants that confer risk of disease. Researchers at Massachusetts General Hospital (MGH), the Broad Institute of MIT and Harvard, and other institutions around the world have now developed a free-access software package called Tractor that increases the discovery power of genomics in understudied populations. A study of Tractor’s performance and accuracy was published in Nature Genetics.
Researchers perform GWAS to identify where genetic variants responsible for causing disease are located in the genome. Recently, geneticists have begun creating models from published GWAS data to predict risks of disease in individuals. But the clinical utility of these models is currently limited, since most are based on genomic studies of people with European ancestry.
“If you build disease-risk models on available data and attempt to extrapolate them to diverse populations, the accuracy of predicting who will get sick is reduced,” says Elizabeth Atkinson, PhD, lead author of the paper and an investigator in the Analytic and Translational Genetics Unit (ATGU) at MGH. “These errors exacerbate existing health disparities, in part because we aren’t finding specific gene variants that may contribute to higher risk of a particular disease in diverse populations.”
Another significant shortcoming of current GWAS is that “they leave many opportunities for genetic discovery on the table for all populations,” says Atkinson. People of African descent, for example, have a million more genetic variations on average than someone who doesn’t have African ancestry due to human migration patterns over the ages. Conducting a GWAS with diverse populations allows geneticists to pinpoint genetic associations to disease at many more spots across the genome, says Atkinson.
“Within these genomic regions identified in a GWAS, the genetic mutation that actually causes disease is shared across ancestries most of the time,” she adds. By studying admixed populations — people with recent ancestry from two or more previously isolated population groups, such as Africa and Europe — “we can get more powerful and precise genetic association signals and do a better job at pinpointing where the causal mutation is, which improves our understanding of disease for everyone.”
Until now, there was no fine-scale way to control for ancestry composition in mixed groups being studied in a GWAS. “Different ancestry groups have gene variants that occur at different frequencies due to the populations’ demographic history,” explains Atkinson. “Not taking ancestry into account in a GWAS can lead to false-positive hits or to gene variants cancelling themselves out and dismissed as not important. So, until now, it’s been easier to exclude people with multiple ancestries from GWAS to avoid being confounded by different patterns of gene variants.”
Tractor, however, allows researchers to account for ancestry in a precise manner so admixed individuals can be included in large-scale gene discovery efforts. The software colors pieces of each person’s chromosomes according to its ancestry origin, which researchers can infer from reference genome sequences, and uses this information in a new GWAS model. “Tractor takes into account the ancestry backbone of each genetic variant so we can correctly calibrate the GWAS results to find causal variants in specific population groups,” says Atkinson.
Tractor also provides estimates of ancestry-specific effect sizes, which isn’t possible in a standard GWAS. “Instead of getting a weighted average of the disease-risk effect size for a particular gene variant, Tractor can determine how large or small the effect of a variant is in various ancestry groups,” says Atkinson. “This will be informative for building genetic risk scores in diverse populations.” Another advantage of Tractor is its ability to improve the power of GWAS by detecting risk gene variants across multiple ancestries. “With Tractor, we can get stronger disease-association signals by leveraging ancestral genomic differences,” says Atkinson.
“Tractor advances the existing methodologies for studying the genetics of complex disorders in diverse and minority populations,” she adds. “We hope that this method increases the inclusion of admixed participants in large-scale association studies going forward.”
Major funding for this study was provided by the National Institute of Mental Health.
Co-authors include Mark Daly, PhD, founding chief of the ATGU and associate professor of Medicine at Harvard Medical School (HMS); and Benjamin Neale, PhD, also of the ATGU, is associate professor of Medicine at HMS and director of Population Genetics, Stanley Center for Psychiatric Research, at the Broad Institute.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
MRI analysis that measures the activity of the glymphatic system may offer a noninvasive method for diagnosing unexplained brain pressure.
A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early morning shift workers with shift work disorder stay more alert.
A national clinical trial led by investigators at Mass General Brigham Cancer Institute has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations.
Mass General Brigham-developed system achieved high accuracy in validation studies, prompting release on open source to enable further investigations.
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.
A new study by Mass General Brigham investigators identifies mutations that drive clinical resistance to rezatapopt treatment.